Use of Renin–Angiotensin–Aldosterone System Inhibitors in Older Patients with Heart Failure and Reduced Ejection Fraction

Patients enrolled in randomised clinical trials may not be representative of the real-world population of people with heart failure (HF). Older patients are frequently excluded and this limits the strength of evidence which supports the use of specific HF treatments in this patient group. Lack of ev...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Davide Stolfo, Gianluigi Savarese
Formato:	article
Lenguaje:	EN
Publicado:	Radcliffe Medical Media 2019
Materias:	Diseases of the circulatory (Cardiovascular) system RC666-701
Acceso en línea:	https://doaj.org/article/f4ce5f907c0d4c6c8732a6a7a88c5b12
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:f4ce5f907c0d4c6c8732a6a7a88c5b12
record_format	dspace
spelling	oai:doaj.org-article:f4ce5f907c0d4c6c8732a6a7a88c5b122021-12-04T16:01:34ZUse of Renin–Angiotensin–Aldosterone System Inhibitors in Older Patients with Heart Failure and Reduced Ejection Fraction10.15420/cfr.2019.6.22057-75592057-7540https://doaj.org/article/f4ce5f907c0d4c6c8732a6a7a88c5b122019-05-01T00:00:00Zhttps://www.cfrjournal.com/articles/Renin-Angiotensin-Aldosterone-Heart-Failure-HFrEFhttps://doaj.org/toc/2057-7540https://doaj.org/toc/2057-7559Patients enrolled in randomised clinical trials may not be representative of the real-world population of people with heart failure (HF). Older patients are frequently excluded and this limits the strength of evidence which supports the use of specific HF treatments in this patient group. Lack of evidence together with fear of adverse effects, drug interactions and lower tolerance may lead to the undertreatment of older patients and a less favourable outcome. Renin–angiotensin–aldosterone system (RAAS) inhibitors are the cornerstone of treatment for patients with HF with reduced ejection fraction (HFrEF), but despite the class I recommendation for all patients regardless of age in the guidelines, there are signs that RAAS inhibitors are underused among older patients. Large registry- based studies suggest that RAAS inhibitors may be at least as effective in older patients as younger ones, but these findings need to be confirmed by randomised clinical trials.Davide StolfoGianluigi SavareseRadcliffe Medical MediaarticleDiseases of the circulatory (Cardiovascular) systemRC666-701ENCardiac Failure Review , Vol 5, Iss 2, Pp 70-73 (2019)
institution	DOAJ
collection	DOAJ
language	EN
topic	Diseases of the circulatory (Cardiovascular) system RC666-701
spellingShingle	Diseases of the circulatory (Cardiovascular) system RC666-701 Davide Stolfo Gianluigi Savarese Use of Renin–Angiotensin–Aldosterone System Inhibitors in Older Patients with Heart Failure and Reduced Ejection Fraction
description	Patients enrolled in randomised clinical trials may not be representative of the real-world population of people with heart failure (HF). Older patients are frequently excluded and this limits the strength of evidence which supports the use of specific HF treatments in this patient group. Lack of evidence together with fear of adverse effects, drug interactions and lower tolerance may lead to the undertreatment of older patients and a less favourable outcome. Renin–angiotensin–aldosterone system (RAAS) inhibitors are the cornerstone of treatment for patients with HF with reduced ejection fraction (HFrEF), but despite the class I recommendation for all patients regardless of age in the guidelines, there are signs that RAAS inhibitors are underused among older patients. Large registry- based studies suggest that RAAS inhibitors may be at least as effective in older patients as younger ones, but these findings need to be confirmed by randomised clinical trials.
format	article
author	Davide Stolfo Gianluigi Savarese
author_facet	Davide Stolfo Gianluigi Savarese
author_sort	Davide Stolfo
title	Use of Renin–Angiotensin–Aldosterone System Inhibitors in Older Patients with Heart Failure and Reduced Ejection Fraction
title_short	Use of Renin–Angiotensin–Aldosterone System Inhibitors in Older Patients with Heart Failure and Reduced Ejection Fraction
title_full	Use of Renin–Angiotensin–Aldosterone System Inhibitors in Older Patients with Heart Failure and Reduced Ejection Fraction
title_fullStr	Use of Renin–Angiotensin–Aldosterone System Inhibitors in Older Patients with Heart Failure and Reduced Ejection Fraction
title_full_unstemmed	Use of Renin–Angiotensin–Aldosterone System Inhibitors in Older Patients with Heart Failure and Reduced Ejection Fraction
title_sort	use of renin–angiotensin–aldosterone system inhibitors in older patients with heart failure and reduced ejection fraction
publisher	Radcliffe Medical Media
publishDate	2019
url	https://doaj.org/article/f4ce5f907c0d4c6c8732a6a7a88c5b12
work_keys_str_mv	AT davidestolfo useofreninangiotensinaldosteronesysteminhibitorsinolderpatientswithheartfailureandreducedejectionfraction AT gianluigisavarese useofreninangiotensinaldosteronesysteminhibitorsinolderpatientswithheartfailureandreducedejectionfraction
_version_	1718372769760018432

Use of Renin–Angiotensin–Aldosterone System Inhibitors in Older Patients with Heart Failure and Reduced Ejection Fraction

Ejemplares similares